Tg Therapeutics (TGTX) Current Assets (2010 - 2026)

Tg Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Current Assets rose 68.65% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 68.65% YoY), while the FY2025 annual figure was $630.8 million, up 11.37% from the prior year.
• Current Assets was $1.1 billion for Q1 2026 at Tg Therapeutics, up from $630.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.1 billion in Q1 2026 to a low of $168.3 million in Q4 2022.
• Historically, Current Assets has averaged $431.9 million across 5 years, with a median of $360.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Current Assets tumbled 55.49% in 2022, then surged 95.14% in 2024.
• A 5-year view of Current Assets shows it stood at $168.3 million in 2022, then surged by 88.94% to $317.9 million in 2023, then surged by 78.13% to $566.4 million in 2024, then gained by 11.37% to $630.8 million in 2025, then surged by 72.33% to $1.1 billion in 2026.
• The last three Current Assets figures came in at $1.1 billion (Q1 2026), $630.8 million (Q4 2025), and $599.8 million (Q3 2025), per Business Quant data.